Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A...

Area of Science:

• Oncology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations drive advanced non-small-cell lung cancer (NSCLC).
• Third-generation EGFR tyrosine kinase inhibitors (TKIs) offer targeted therapy for EGFR mutation-positive (EGFRm) NSCLC.

Purpose of the Study:

• To evaluate the efficacy and safety of first-line osimertinib in Chinese patients with EGFRm advanced NSCLC.
• To compare osimertinib with standard EGFR TKIs (gefitinib or erlotinib) in this population.

Main Methods:

• A double-blind, randomized, phase III FLAURA China study.
• 136 adult patients with previously untreated EGFRm advanced NSCLC were randomized to osimertinib or comparator EGFR TKI.
• Primary endpoint: investigator-assessed progression-free survival (PFS); Secondary endpoint: overall survival (OS).

Main Results:

• Osimertinib significantly extended median PFS by 8.0 months (17.8 vs. 9.8 months) versus comparator.
• Median OS was 33.1 months with osimertinib versus 25.7 months with comparator.
• Grade 3+ adverse events were higher with osimertinib (54% vs. 28%), consistent with known safety profile; no new signals identified.

Conclusions:

• First-line osimertinib provides a clinically meaningful PFS and OS benefit in Chinese patients with EGFRm advanced NSCLC.
• The safety profile of osimertinib in this study is consistent with previous findings.
• Osimertinib represents an effective first-line treatment option for this patient group.